| Literature DB >> 27155899 |
Xiaokai Li1, Jiayi Shen1, Li Tan2, Zhang Zhang3, Donglin Gao2, Jinfeng Luo3, Huimin Cheng3, Xiaoping Zhou1, Jie Ma1, Ke Ding4, Xiaoyun Lu5.
Abstract
B-Raf(V600E) was an effective target for the treatment of human cancers. Based on a pan-Raf inhibitor TAK-632, a series of N-(4-aminopyridin-2-yl)amide derivatives were designed as novel B-Raf(V600E) inhibitors. Detailed structure-activity studies of the compounds revealed that most of the compounds displayed potent enzymatic activity against B-Raf(V600E), and good selectivity over B-Raf(WT). One of the most promising compound 4l exhibited potent inhibitory activity with an IC50 value of 38nM for B-raf(V600E), and displayed antiproliferative activities against colo205 and HT29 cells with IC50 values of 0.136 and 0.094μM, respectively. It also displayed good selectivity on both enzymatic and cellular assays over B-Raf(WT). These inhibitors may serve as lead compounds for further developing novel B-Raf(V600E) inhibitors as anticancer drugs.Entities:
Keywords: B-Raf(V600E) inhibitor; N-(4-Aminopyridin-2-yl)amides; Selective; Structural modification
Mesh:
Substances:
Year: 2016 PMID: 27155899 DOI: 10.1016/j.bmcl.2016.04.076
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823